about
Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytesImmunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiencyChildhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysisInternational and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus.Brief Report: Childhood-Onset Systemic Necrotizing Vasculitides: Long-Term Data From the French Vasculitis Study Group Registry.Tolerance of efavirenz in children.Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment.Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients.Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency.EBV-negative lymphoproliferative disease with hyper-IgA, in a child with combined liver and small bowel transplantation.Haematopoetic stem cell transplantation for refractory autoimmune cytopenia.Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.Long-term outcomes of hematopoietic stem cell transplantation for severe treatment-resistant autoimmune cytopenia in children.LRBA deficiency with autoimmunity and early onset chronic erosive polyarthritis.Clinical features of childhood granulomatosis with polyangiitis (wegener's granulomatosis)Cryopyrinopathies: update on pathogenesis and treatment.EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation.Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry.Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study.A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes.Use of canakinumab in the cryopyrin-associated periodic syndrome.Immunodeficiency and genetic conditions that cause arthritis in childhood.Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kindAutologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidityEfficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.Abdominal manifestations in childhood-onset systemic lupus erythematosus.Foveal Serous Retinal Detachment in Juvenile Idiopathic Arthritis-associated Uveitis.Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent.Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.ADA2 deficiency: case report of a new phenotype and novel mutation in two sistersClinical outcome in children with chronic recurrent multifocal osteomyelitis.The PRINTO criteria for clinically inactive disease in juvenile dermatomyositisEfficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies.RNA recognition by human TLR8 can lead to autoimmune inflammation.Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy.Juvenile idiopathic arthritis: classification, clinical presentation and current treatments.Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease.
P50
Q24298360-02F384B3-49BB-4EC1-9E97-F25DFE6F54C9Q24301912-D0C3FD9D-41CB-4FC3-BE8C-D99194468057Q28069646-4F3A074B-00FB-4D65-975C-7B76F9D755BBQ30234696-0EB9E744-92EC-406C-896D-DC6EEE769124Q30916093-6C2419C0-C6AA-45E4-853D-58568E2A8179Q32054843-584FDA1A-5C70-4F63-AD23-8ABA0A3C191AQ33346179-8EB1A007-728F-4F6E-8F88-01AD76C26B5BQ33347855-0A3E0723-EC88-48FE-8292-BF8CE343B40AQ33359560-3996F350-20A0-441E-B5D0-146A7BFCB7B0Q33361117-20EA9585-9847-4095-B7DE-8E3D1B268353Q33361139-360BD1F1-0461-4E09-88CD-A689C1F90C43Q33404895-F14AE238-55DA-476A-A627-524C38DF6C29Q33404904-35F5556D-E846-43AA-95F9-871F91D13F19Q33431338-022222DF-DE20-45E1-97B6-8656794F3288Q33696589-F128CB1B-EE6A-4C11-9B41-C4172E80A84DQ34013074-C0464D22-C831-4668-9C1F-81C2EDCB7A88Q34109962-925D245F-36CE-4DD1-A29C-FB3CD18A65C5Q34429717-094E19EE-970A-43DA-BB9F-451BAE58518CQ34594335-7BE1A33D-D6C7-46B8-BB8C-DC98B5671E7BQ34619656-156D3724-62AA-4D8D-B4E0-C1F47884E56EQ34632661-2642550B-1718-4167-8FB2-1F613A61C9A2Q34758768-885A2EDE-31E3-47A1-AF06-3E6208DC6925Q34895303-FDD34215-8988-41BA-B5EC-9FC4069A43F7Q34984749-F836904C-2851-400F-ACAA-DE0D2629E280Q34994477-FCA6FE11-7E37-45C5-969D-0683637153CAQ35190461-02E535BF-8DA5-4ADB-9DEF-19DF15E2D00EQ35553325-B1CCFA75-3F5F-4803-951C-92CA2E495A5DQ35605487-897FADBC-9A70-4F53-9646-B392ED56AD8EQ35638742-52C253BA-34DD-4DFD-9BFB-4071F5CF8382Q35690424-B811C009-C3CB-475E-B0FC-7ED645F5C7B2Q36183846-545C9E79-7C69-4968-BFFC-B875F5F497F9Q36346681-32659D04-8AB9-472F-A521-BED80D69BD5EQ36933267-A6268319-BFB4-4AE3-861C-F6BF7BE9D29AQ37214206-4BB0B684-EB5C-483C-AC41-FBD224AC9CD4Q37293030-3935C645-E1D2-4D84-9B6C-9A949C9AC50CQ37345479-5FFFAF97-2D6B-437F-8DBE-99CA5E712313Q37397807-A5CB4994-B1C7-4B2F-BAD2-C8730CD9F4F8Q37602644-4645F426-A7A9-401E-B10E-70C7B6520C1BQ37639013-5859FD39-6D80-4F6F-876D-C1C35B2A8BF5Q37666293-F9DC2714-6D04-4BC3-AFE3-27CCAED7358A
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Pierre Quartier
@ast
Pierre Quartier
@en
Pierre Quartier
@es
Pierre Quartier
@nl
Pierre Quartier
@pt
Pierre Quartier
@sl
type
label
Pierre Quartier
@ast
Pierre Quartier
@en
Pierre Quartier
@es
Pierre Quartier
@nl
Pierre Quartier
@pt
Pierre Quartier
@sl
prefLabel
Pierre Quartier
@ast
Pierre Quartier
@en
Pierre Quartier
@es
Pierre Quartier
@nl
Pierre Quartier
@pt
Pierre Quartier
@sl
P214
P106
P21
P214
P31
P496
0000-0002-1769-549X
P735
P7859
viaf-316665405